Drug Profile


Alternative Names: Revatio; Revatio IV; Sildenafil citrate; UK 92480; Viagra

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Heart failure; Pulmonary hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erectile dysfunction; Pulmonary arterial hypertension
  • Phase III Heart failure; Pulmonary hypertension
  • Clinical Phase Unknown Female infertility; Raynaud's disease
  • Discontinued Angina pectoris; Cardiovascular disorders; Eye disorders; Female sexual dysfunction

Most Recent Events

  • 14 Aug 2017 Pfizer re-initiated the phase III SilHF trial in Heart failure (Treatment-experienced) in United Kingdom, Norway, Italy, Israel (PO) (NCT01616381)
  • 09 Mar 2017 Expanded access no longer available for a trial in Pulmonary arterial hypertension (In children, In adolescents, In adults) in India (NCT01582438)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top